The authors investigate the sufficiency of high-temperature short-time treatment in inactivate mouse minute virus contamination.
Raymond W. Nims, PhD
Advertisement
Raymond W. Nims, PhD, is a biosafety consultant at RMC Pharmaceutical Solutions, Inc.
Articles by Raymond W. Nims, PhD
The authors present a case study identifying a contaminant.
What you need to know about USP chapter <63>.
Avoid manufacturing failures by effective viral inactivation.
Strategies for accurate speciation and case studies for the detection of cell line cross-contamination using a commercial kit.
Advertisement
Latest Updated Articles
Nontuberculosis Mycobacterium Contamination of a Mammalian Cell Bioreactor ProcessPublished: June 1st 2011 | Updated:
USP <63> Mycoplasma Tests: A New Regulation for Mycoplasma TestingPublished: August 1st 2010 | Updated:
Detection of Cache Valley Virus in Biologics Manufactured in CHO CellsPublished: October 1st 2008 | Updated:
Cell Line Authentication Using Isoenzyme AnalysisPublished: June 1st 2005 | Updated:
Modeling the Efficacy of HTST for Inactivating Mouse Minute VirusPublished: April 1st 2016 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4
